Hospital
South Lake Hospital, INC.
South Lake Hospital, INC. was paid $16.88M by Medicaid between Jan 2018 and Dec 2024, across 187 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoSOUTH LAKE HOSPITAL, INC.
CLERMONT, FL 34711
CLERMONT, FL 34711
33aNPI1336221019assigned 10/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.88M
24GClaims534,019
24DCodes billed187
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#26 of 163
Median peer was paid$4.77M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,033 | $712K | |
| 2019 | 88,119 | $1.91M | |
| 2020 | 76,037 | $1.35M | |
| 2021 | 129,919 | $3.79M | |
| 2022 | 122,028 | $4.46M | |
| 2023 | 61,051 | $3.30M | |
| 2024incomplete | 22,832 | $1.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 57,428 | 52,507 | $5.78M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 38,538 | 32,852 | $3.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 9,296 | 7,971 | $827K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.6% | 11,060 | 9,200 | $772K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 3,948 | 3,485 | $702K |
| 80053 | Comprehensive metabolic panel | 3.6% | 28,852 | 23,887 | $605K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 2,352 | 2,085 | $484K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 4,311 | 4,000 | $361K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 1,607 | 1,417 | $230K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 4,329 | 3,756 | $199K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 2,854 | 2,590 | $198K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 28,554 | 22,604 | $181K |
175 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.0% | 1,902 | $170K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,150 | $153K |
| 87631 | <1% | 5,084 | $146K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,650 | $144K |
| 87081 | <1% | 2,720 | $140K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,813 | $132K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,563 | $108K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 440 | $95K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,382 | $84K |
| 59025 | Fetal non-stress test | <1% | 1,352 | $79K |
| 84703 | <1% | 7,033 | $77K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,946 | $67K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 218 | $64K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,167 | $59K |
| 76830 | Ultrasound, transvaginal | <1% | 1,454 | $58K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,526 | $58K |
| G0378 | Hospital observation service, per hour | <1% | 7,117 | $57K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,284 | $56K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 739 | $55K |
| 81003 | <1% | 8,663 | $54K | |
| 87420 | <1% | 860 | $52K | |
| 82962 | <1% | 4,468 | $49K | |
| 81001 | <1% | 16,568 | $47K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,177 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,509 | $40K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 564 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,779 | $31K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,536 | $31K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 10,607 | $30K |
| 84702 | <1% | 2,137 | $28K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,682 | $27K |
| 73610 | <1% | 1,099 | $24K | |
| 73562 | <1% | 1,306 | $23K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,096 | $22K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 849 | $22K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,621 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,371 | $20K |
| 85027 | <1% | 11,814 | $20K | |
| 86850 | <1% | 1,237 | $19K | |
| 73630 | <1% | 1,218 | $18K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 82 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,989 | $16K |
| 84484 | <1% | 9,538 | $16K | |
| 83735 | <1% | 17,081 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 545 | $14K |
| 73130 | <1% | 757 | $13K | |
| 87480 | <1% | 2,003 | $12K | |
| 73110 | <1% | 627 | $12K | |
| 73030 | <1% | 744 | $12K | |
| 12001 | <1% | 217 | $12K | |
| 12011 | <1% | 170 | $11K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 155 | $9K |
| 74018 | <1% | 761 | $9K | |
| 76801 | <1% | 1,196 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,220 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,103 | $8K |
| 93971 | <1% | 650 | $8K | |
| 86900 | <1% | 2,153 | $8K | |
| 85610 | <1% | 2,305 | $8K | |
| 87486 | <1% | 746 | $7K | |
| 87077 | <1% | 769 | $7K | |
| 70491 | <1% | 14 | $7K | |
| 96376 | <1% | 2,775 | $6K | |
| 83880 | <1% | 2,545 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,748 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 254 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,355 | $5K |
| 73140 | <1% | 237 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 206 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,620 | $5K |
| 81025 | <1% | 5,727 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 79 | $4K |
| 72131 | <1% | 572 | $4K | |
| 73080 | <1% | 139 | $4K | |
| 83690 | <1% | 8,734 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,395 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,717 | $3K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 288 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,332 | $3K |
| 01999 | <1% | 547 | $3K | |
| 80061 | Lipid panel | <1% | 2,523 | $2K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 32 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 91 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,175 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 723 | $2K |
| 87507 | <1% | 29 | $2K | |
| 73590 | <1% | 112 | $2K | |
| 93017 | <1% | 100 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,785 | $2K |
| 82550 | <1% | 803 | $2K | |
| 85730 | <1% | 1,645 | $2K | |
| 86901 | <1% | 2,156 | $2K | |
| 87040 | <1% | 1,041 | $2K | |
| 97162 | <1% | 29 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 28 | $2K |
| 72100 | <1% | 227 | $1K | |
| 83605 | <1% | 1,471 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 464 | $1K |
| 87186 | <1% | 1,859 | $1K | |
| 29125 | <1% | 108 | $1K | |
| 85379 | <1% | 1,504 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,415 | $1K |
| 73090 | <1% | 50 | $965.52 | |
| 87510 | <1% | 1,983 | $929.88 | |
| 73660 | <1% | 13 | $888.78 | |
| 00730 | <1% | 15 | $842.14 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,986 | $816.90 |
| 72040 | <1% | 12 | $814.89 | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 12 | $808.92 |
| 76641 | <1% | 59 | $801.58 | |
| 76770 | <1% | 28 | $756.69 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 109 | $714.52 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,802 | $643.73 |
| 77066 | Tomosynthesis, mammo | <1% | 17 | $641.10 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 868 | $638.32 |
| 87581 | <1% | 744 | $595.92 | |
| 87660 | <1% | 1,986 | $517.36 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $514.47 |
| 90715 | <1% | 540 | $472.32 | |
| J2704 | Injection, propofol, 10 mg | <1% | 913 | $417.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,227 | $414.39 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 429 | $372.12 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 91 | $357.90 |
| 85652 | <1% | 811 | $347.50 | |
| 86140 | <1% | 686 | $298.55 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 103 | $264.42 |
| 87340 | <1% | 302 | $260.13 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 517 | $259.13 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 405 | $243.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,649 | $239.96 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 404 | $228.73 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 87 | $222.11 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 171 | $199.81 |
| 84439 | <1% | 709 | $195.07 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $193.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 775 | $185.94 |
| 71250 | <1% | 14 | $171.69 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 459 | $165.25 |
| 86780 | <1% | 44 | $149.78 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,315 | $148.60 |
| 72128 | <1% | 114 | $141.76 | |
| 86803 | <1% | 137 | $118.89 | |
| 82565 | <1% | 29 | $106.44 | |
| 77062 | <1% | 14 | $94.11 | |
| 86592 | <1% | 293 | $89.38 | |
| 84156 | <1% | 111 | $53.70 | |
| 82607 | <1% | 258 | $53.62 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 15 | $45.22 |
| 82746 | <1% | 64 | $19.38 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 323 | $17.21 |
| 87205 | <1% | 74 | $12.92 | |
| 82728 | <1% | 29 | $6.75 | |
| 87210 | <1% | 101 | $5.18 | |
| 82570 | <1% | 137 | $4.93 | |
| 86308 | <1% | 97 | $3.16 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 809 | $0.60 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 282 | $0.04 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 234 | $0.00 |
| 83540 | 0% | 20 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 660 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 493 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 131 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 120 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 153 | $0.00 |
| 96367 | 0% | 13 | $0.00 | |
| 99219 | 0% | 49 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 14 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 34 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 380 | $0.00 |
| 73502 | 0% | 55 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 15 | $0.00 |
| 86762 | 0% | 24 | $0.00 | |
| 82043 | 0% | 44 | $0.00 | |
| 83550 | 0% | 19 | $0.00 | |
| 87147 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNAPIER, MICHELE (CHIEF REVENUE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Orlando Health, INC. | Orlando, FL | $105.45M |
| Orlando Health Medical Group INC | Orlando, FL | $57.49M |
| Orlando Physicians Network INC | Orlando, FL | $9.44M |
| Baptist Health Centers LLC | Talladega, AL | $6.99M |
| Baptist Health Centers, LLC | Winfield, AL | $2.15M |
| Baptist Health Centers LLC | Talladega, AL | $2.00M |
| Ohi West Medical Group, LLC | St Petersburg, FL | $1.28M |
| Orlando Regional Healthcare | Orlando, FL | $1.01M |
| Baptist Health Centers, LLC | Lincoln, AL | $988K |
| BW Physician Practices, LLC | Birmingham, AL | $967K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.